查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712511

全球3D生物列印市场 - 2025-2033

Global 3D Bioprinting Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 165 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球 3D 生物列印市场规模达到 34.5 亿美元，预计到 2033 年将达到 302.8 亿美元，在 2025-2033 年预测期内的复合年增长率为 24.2%。

3D 生物列印是一种使用数位模型创建三维结构的先进製造技术。它们应用于医疗保健、汽车和航太等行业。生物列印是 3D 列印的一个专业分支，涉及生物墨水的逐层沉积，结合活细胞和生物材料来创建类似组织的结构。该技术在再生医学、药物测试和器官移植研究方面具有潜力。它们共同彻底改变了产品设计和製造，提供了更高的精度、客製化和创新性。

市场动态：

驾驶员和约束装置

组织工程和再生医学的进展

全球 3D 生物列印市场受到组织工程和再生医学进步的推动。生物列印技术能够创建皮肤、软骨和微型器官等复杂的组织结构，为药物测试、疾病建模和器官移植提供了潜力。这些创新减少了动物试验并加速了个人化治疗。随着研究机构和生物技术公司大力投资，对生物印表机和生物墨水的需求预计将会成长。

例如，2024年4月中国石油大学、浙江大学和特拉维夫大学合作，探索利用胜肽自组装技术和3D列印技术开发复杂的生物结构和器官，为未来生物医学应用奠定基础。

监管和道德挑战

由于对安全、同意和滥用的担忧，全球 3D 生物列印市场面临监管和道德挑战。现有的监管架构往往不够完善，导致商业化和临床应用的延迟。这种不确定性可能会阻碍投资和创新，尤其是在医疗监管较为严格的地区，进而影响市场扩张。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按组件截取片段
  • 技术片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 组织工程和再生医学的进展
      • 製药和化妆品行业的应用日益广泛
    • 限制
      • 监管和道德挑战
      • 缺乏合格的专业人员
    • 机会
      • 个人化医疗和药物测试的兴起
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大、最畅销品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：按组件

  • 3D印表机
  • 生物材料
  • 支架

第六章：3D生物列印市场（依技术）

  • 基于喷墨的生物列印
  • 磁浮
  • 基于注射器的生物列印
  • 基于雷射的生物列印
  • 其他的

第七章：3D生物列印市场（按应用）

  • 静脉穿刺协助
  • 医疗药丸
  • 义肢和植入物
  • 牙科
  • 生物感测器
  • 消费者/个人产品测试
  • 生物墨水
  • 食品和动物产品

第 8 章：3D 生物列印市场（依最终用户划分）

  • 研究机构和学术机构
  • 生物製药公司
  • 医院
  • 其他的

第九章：3D 生物列印市场、区域市场分析与成长机会

  • 北美洲
    • 关键区域特定动态
      • 我们
      • 加拿大
      • 墨西哥
  • 欧洲
    • 关键区域特定动态
      • 德国
      • 英国
      • 法国
      • 西班牙
      • 义大利
      • 欧洲其他地区
  • 南美洲
    • 关键区域特定动态
      • 巴西
      • 阿根廷
      • 拉丁美洲其他地区
  • 亚太
    • 关键区域特定动态
      • 中国
      • 印度
      • 日本
      • 韩国
      • 亚太其他地区
  • 中东和非洲
    • 关键区域特定动态

第十章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第 11 章：公司简介

  • 3D Systems Corporation
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • EnvisionTEC GmbH
  • Stratasys Ltd
  • Cyfuse Biomedical KK
  • Cellink
  • Poietis
  • RegenHU SA

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: MD6751

The global 3D bioprinting market reached US$ 3.45 billion in 2024 and is expected to reach US$ 30.28 billion by 2033, growing at a CAGR of 24.2% during the forecast period 2025-2033.

3D bioprinting is are advanced manufacturing technologies that create three-dimensional structures using digital models. They are used in industries like healthcare, automotive, and aerospace. Bioprinting, a specialized branch of 3D printing, involves layer-by-layer deposition of bioinks, combining living cells and biomaterials to create tissue-like structures. This technology has potential in regenerative medicine, drug testing, and organ transplantation research. Together, they revolutionize product design and manufacturing, offering enhanced precision, customization, and innovation.

Market Dynamics: Drivers & Restraints

Advancements in Tissue Engineering and Regenerative Medicine

The global 3D bioprinting market is driven by advancements in tissue engineering and regenerative medicine. Bioprinting technologies enable the creation of complex tissue structures like skin, cartilage, and miniature organs, offering the potential for drug testing, disease modeling, and organ transplantation. These innovations reduce animal testing and accelerate personalized therapies. As research institutions and biotech companies invest heavily, demand for bioprinters and bioinks is expected to grow.

For instance, in April 2024 by China University of Petroleum, Zhejiang University, and Tel Aviv University explored the use of peptide self-assembly technology and 3D printing for developing complex biological structures and organs, laying the foundation for future biomedical applications.

Regulatory and Ethical Challenges

The global 3D bioprinting market faces regulatory and ethical challenges due to concerns about safety, consent, and misuse. Existing regulatory frameworks are often inadequate, leading to delays in commercialization and clinical adoption. This uncertainty can hinder investment and innovation, especially in regions with stricter medical regulations, affecting market expansion.

Segment Analysis

The global 3D bioprinting market is segmented based on component, technology, application, end-user, and region.

Component:

The 3D printers from the component segment are expected to dominate the 3D bioprinting market with the highest market share

3D printers are advanced devices that use additive manufacturing to create intricate biological structures by depositing bio-inks layer by layer. These bioinks, often containing living cells, biomaterials, and growth factors, mimic natural human tissues and organs. They are widely used in regenerative medicine, drug development, and disease modeling, enabling researchers to study cellular behavior and develop personalized treatments.

The global demand for 3D printers is driven by the growing demand for organ and tissue transplants, regenerative medicine investments, and personalized healthcare. Advancements in biomaterials and bioprinting technologies have improved tissue precision, expanding their use in clinical and research settings. Government support, regulatory developments, and partnerships between research institutes and biotech companies are also driving this growth.

For instance, in November 2024, University of Melbourne biomedical engineers developed a 3D bioprinter capable of creating structures that resemble various human body tissues, including soft brain tissue and harder materials like cartilage and bone.

Geographical Analysis

North America is expected to hold a significant position in the 3D bioprinting market with the highest market share

North America dominates the global 3D bioprinting market due to strong research, robust healthcare infrastructure, and early adoption of advanced technologies. The presence of biotech companies, research institutions, and universities in tissue engineering and regenerative medicine has accelerated bioprinting innovation. Government funding and regulatory frameworks, particularly in the U.S., promote 3D printing for medical applications like prosthetics, implants, and personalized healthcare solutions. The growing demand for organ transplantation alternatives and personalized medicine further drives the use of bioprinting technologies.

For instance, in June 2024, Tethon 3D, a Nebraska-based ceramic 3D printing specialist, launched the Bison Bio DLP 3D printer, a desktop-sized system designed for medical R&D applications. The system is compatible with Tethin 3D's Tethon LAP photoinitiator and Tethon GelMA hydrogel bioink, produced in partnership with Cell Bark Innovation, a biomaterial firm.

Competitive Landscape

The major global players in the 3D Bioprinting market include 3D Systems Corporation, EnvisionTEC GmbH, Stratasys Ltd, Cyfuse Biomedical KK, Cellink, Poietis, and RegenHU SA, among others.

Key Developments

  • In November 2024, SCTIMST developed India's first Indigenous patented bioink formulation for fabricating liver, kidney, pancreas, skin, brain, and heart tissues using advanced 3D bioprinting technology, using advanced 3D printing technology.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global 3D bioprinting market report delivers a detailed analysis with 70 key tables, more than 74 visually impactful figures, and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Component
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Tissue Engineering and Regenerative Medicine
      • 3.1.1.2. Growing Adoption in Pharmaceutical and Cosmetic Industries
    • 3.1.2. Restraints
      • 3.1.2.1. Regulatory and Ethical Challenges
      • 3.1.2.2. Lack of Qualified Professionals
    • 3.1.3. Opportunity
      • 3.1.3.1. Rise in Personalized Medicine and Drug Testing
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Component

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 5.1.2. Market Attractiveness Index, By Component
  • 5.2. 3D Printers*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Biomaterials
  • 5.4. Scaffolds

6. 3D Bioprinting Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Inkjet-Based Bioprinting*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Magnetic Levitation
  • 6.4. Syringe-Based Bioprinting
  • 6.5. Laser-Based Bioprinting
  • 6.6. Others

7. 3D Bioprinting Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Venipuncture Assistance*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Medical Pills
  • 7.4. Prosthetics and Implants
  • 7.5. Dental
  • 7.6. Biosensors
  • 7.7. Consumer/Personal Product Testing
  • 7.8. Bioinks
  • 7.9. Food and Animal Products

8. 3D Bioprinting Market, By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Research Organizations and Academic Institutes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Biopharmaceutical Companies
  • 8.4. Hospitals
  • 8.5. Others

9. 3D Bioprinting Market, Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. 3D Systems Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. EnvisionTEC GmbH
  • 11.3. Stratasys Ltd
  • 11.4. Cyfuse Biomedical KK
  • 11.5. Cellink
  • 11.6. Poietis
  • 11.7. RegenHU SA

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us